Oppenheimer Initiates Coverage on Eurand (EURX)
More News related to EURX
- Eurand N.V. (EURX) Announces Availability of ZENPEP
- Eurand Launches ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules
- Eurand (EURX) Announced Phase II/III Data for Pancreatic Enzyme Product ZENPEP
- Phase II/III Clinical Study Compares Safety and Efficacy of Two Doses of ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules for Fat Absorption in Adult Chronic Pancreatitis Patients With Exocrine Panc
- Eurand Reports Key Achievements and Strong Revenue Growth for Third Quarter 2009
More News related to New Coverage
- Deutsche Bank Starts Coverage on Utilities Stocks: CMS, AEP, EIX, ITC, PSEG at Buy
- Keefe, Bruyette and Woods Initiates Coverage of Taubman Centers (TCO) with an Outperform
- Keefe, Bruyette and Woods Initiates Coverage of Simon Property Group (SPG) with an Outperform
- Keefe, Bruyette and Woods Initiates Coverage of Tanger Factory Outlet Centers (SKT) with a Market Perform
- Keefe, Bruyette and Woods Initiates Coverage of Pennsylvania REIT (PEI) with a Market Perform
Oppenheimer initiates coverage on Eurand (Nasdaq: EURX) with an Outperform. Price target $16.
To see more analyst ratings on EURX Click Here.
Eurand N.V. (Eurand), formerly known as Eurand B.V., is a specialty pharmaceutical company.
Related Categories
New CoverageStocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
